Navigation Links
Tel Aviv University Fertility Research Confirms New York Center's DHEA Findings
Date:7/9/2010

Tel Aviv University's recent findings on the supplementation of DHEA to improve fertility in women with diminished ovarian reserve further confirms Center For Human Reproduction's ongoing research on this treatment.

(PRWEB) July 9, 2010 -- A study conducted by Adrian Shulman, MD and co-workers of Tel Aviv University in Tel Aviv, Israel, confirmed previously published research by New York City’s Center for Human Reproduction (CHR) about the positive effects of the supplement dehydroepiandrosterone (DHEA) in improving fertility in women with diminished ovarian reserve. Dr. Shulman’s study, which featured only 33 women, 17 on DHEA and 16 controls, represents the first prospectively randomized study of DHEA in infertility. It confirmed prior published reports from CHR that DHEA increases the likelihood of conception with in vitro fertilization (IVF) approximately threefold.

New York’s CHR pioneered the use of DHEA and has been using DHEA supplementation in women with diminished ovarian reserve since 2004. CHR researchers, under the leaderships of Norbert Gleicher, MD, the center’s Medical Director, and David H. Barad, MD, its Director of Clinical Assisted Reproduction, previously published a number of controlled studies of various designs demonstrating the benefits of DHEA in increasing fertility in prestigious peer-reviewed medical journals – such as Fertility and Sterility, Human Reproduction and the Journal of Assisted Reproduction and Genetics – which contributed to the increasing popularity of DHEA supplementation world-wide. CHR’s prior studies are, indeed, fully referenced in the scientific paper by Shulman and associates, though left unmentioned in the press release, accompanying publication of their study.

Based on prior research CHR, indeed, in 2009 was awarded a United States patent for the use of DHEA in treating infertility in women with diminished ovarian reserve. Over 2,000 women from all over the U.S. and the world so far received treatment with DHEA at CHR, either because of diminished ovarian reserve due to advanced age or premature ovarian aging. This comparatively very large experience contributes to CHR’s world-wide reputation as a “fertility center of last resort.”

By successfully recruiting 33 women into a prospectively randomized study, of which 17 received DHEA, Dr. Shulman’s group achieved a key research milestone that CHR, despite several attempts over six years, failed to realize. As, however, quoted in their paper, but omitted by the paper’s press release, researchers and physicians, including Dr. Shulman and associates, started utilizing DHEA worldwide only based on earlier CHR research and publications.

The study by Shulman and associates represents an important step forward in confirming the beneficial effects of DHEA in female infertility and the investigators are to be congratulated on their efforts.
Further information about CHR's DHEA treatments and research can be found by visiting: http://www.centerforhumanreprod.com/dhea.html

About Center for Human Reproduction
Center for Human Reproduction (CHR) is one of the leading fertility centers in the United States. A provider of fertility services to both men and women, CHR is also a research and educational organization, holding a number of patents in the field of human fertility. More information about CHR can be found online by visiting www.centerforhumanreprod.com or by calling 212-994-4400.

###

Read the full story at http://www.prweb.com/releases/2010/07/prweb4236634.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
2. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
3. Most pandemic plans in Ontario hospitals have not been tested: Queens University study
4. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
5. Smithsonian Institution, Arizona State University announce education and research partnership
6. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
7. Giarmarco, Mullins & Horton, P.C. President Joseph F. Page to Speak at University of Michigan
8. Arizona State Universitys Decision Theater offers balance to an off-kilter world
9. Forest City Announces Joint Venture with Health Care REIT for University Park Life Science Properties
10. Herzing University Online Launches Master and Bachelor of Science Degrees in Nursing
11. Nurtur Acquires ActivHealth and Wellness by Choice; Gains Exclusive Partnership with Duke University Center for Living
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... With the ... created the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about ... Dentistry, the dental implant and prosthetic market in the U.S. is projected to reach ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... to its innovative Unified Instance Manager architecture, meeting the needs of multichannel ... version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides greater ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology: